About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vera Therapeutics, Inc. - Class A Common Stock (NQ:VERA)

39.55 -1.23 (-3.03%)
Streaming Delayed Price Updated: 10:07 AM EST, Mar 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 191,256
Open 39.95
Bid (Size) 39.40 (100)
Ask (Size) 39.64 (100)
Prev. Close 40.79
Today's Range 39.01 - 40.49
52wk Range 18.53 - 56.05
Shares Outstanding 44,261,109
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics to Participate at Upcoming Investor Conferences
From Vera Therapeutics
Via GlobeNewswire

Performance

YTD
-18.6%
-18.6%
1 Month
-8.6%
-8.6%
3 Month
+19.9%
+19.9%
6 Month
+74.9%
+74.9%
1 Year
+39.2%
+39.2%

More News

Read More
News headline image
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Vera Therapeutics
Via GlobeNewswire
News headline image
Why Vera Therapeutics Stock Zoomed Higher Today ↗
Via The Motley Fool
News headline image
Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
News headline image
Why Vera Therapeutics Stock Rocked the Market on Tuesday ↗
Via The Motley Fool
News headline image
Why Vera Therapeutics Stock Crushed it Today ↗
Via The Motley Fool
News headline image
Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors
From Vera Therapeutics
Via GlobeNewswire
News headline image
Get insights into the top gainers and losers of Tuesday's after-hours session. ↗
Via Chartmill
News headline image
Vera Therapeutics to Participate at Upcoming Investor Conferences
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine
From Vera Therapeutics
Via GlobeNewswire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
Via Benzinga
News headline image
VERA THERAPEUTICS INC (NASDAQ:VERA) Reports Q3 2025 Earnings, Misses EPS Estimates Amid Key Clinical Progress ↗
Via Chartmill
Topics Earnings
News headline image
Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
From Vera Therapeutics
Via GlobeNewswire
News headline image
Capricorn Fund Loads Up on Phreesia (PHR) With a 484,000 Share Purchase ↗
Via The Motley Fool
News headline image
Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET
From Vera Therapeutics
Via GlobeNewswire

Frequently Asked Questions

Is Vera Therapeutics, Inc. - Class A Common Stock publicly traded?
Yes, Vera Therapeutics, Inc. - Class A Common Stock is publicly traded.
What exchange does Vera Therapeutics, Inc. - Class A Common Stock trade on?
Vera Therapeutics, Inc. - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Vera Therapeutics, Inc. - Class A Common Stock?
The ticker symbol for Vera Therapeutics, Inc. - Class A Common Stock is VERA on the Nasdaq Stock Market
What is the current price of Vera Therapeutics, Inc. - Class A Common Stock?
The current price of Vera Therapeutics, Inc. - Class A Common Stock is 39.55
When was Vera Therapeutics, Inc. - Class A Common Stock last traded?
The last trade of Vera Therapeutics, Inc. - Class A Common Stock was at 03/02/26 10:07 AM ET
What is the market capitalization of Vera Therapeutics, Inc. - Class A Common Stock?
The market capitalization of Vera Therapeutics, Inc. - Class A Common Stock is 1.75B
How many shares of Vera Therapeutics, Inc. - Class A Common Stock are outstanding?
Vera Therapeutics, Inc. - Class A Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.